Polaris beats top-line and bottom-line estimates; raises FY26 outlook

Ares Capital in charts: Q3 gross commitments drop 46.3% Y/Y to $2.11B; dividend income rises 13.5%

2026/10/27

GSK to nearly double cancer drugs in late-stage trials next year: WSJ

2026/10/27

Target adds more style to its in-house Threshold brand

2026/10/27

Ares Capital stock dips as slower transaction environment hits Q3 earnings

2026/10/27